Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01077284 · ClinicalTrials.gov registry record · Phase 2
Febuxostat Versus Allopurinol or Placebo in Patients With Hyperuricosuria and Calcium Oxalate Stones
A Phase 2 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 2
- Development phase
- 99
- Enrollment target
NCT01077284 is a Phase 2 study that has completed, run by Takeda. The registered enrollment target is 99 participants.
The verdict
NCT01077284, a Phase 2 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 99 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the efficacy of febuxostat, once daily (QD), compared to allopurinol or placebo in patients with excessive amounts of uric acid in their urine and who have recently had kidney stones.
Interventions
- DRUG Placebo
- DRUG Allopurinol
- DRUG Febuxostat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2010-02 |
| Est. Completion | 2011-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01077284
The ClinicalTrials.gov registry entry for NCT01077284 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 99 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01077284 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01077284 about?
NCT01077284 is a clinical study titled "Febuxostat Versus Allopurinol or Placebo in Patients With Hyperuricosuria and Calcium Oxalate Stones". The purpose of this study is to determine the efficacy of febuxostat, once daily (QD), compared to allopurinol or placebo in patients with excessive amounts of uric acid in their urine and who have recently had kidney stones.
What is the current status of trial NCT01077284?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 99 participants. The study started on 2010-02. Estimated completion is 2011-11.
What interventions are being tested in trial NCT01077284?
The interventions under investigation include: Placebo (DRUG), Allopurinol (DRUG), Febuxostat (DRUG).
Who is sponsoring clinical trial NCT01077284?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.